These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20806349)

  • 1. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Keating MJ; Brown JR; Gribben JG; Browning M; Rassenti LZ; Greaves AW; Neuberg D; O'Brien SM;
    Cancer; 2011 Jan; 117(1):116-24. PubMed ID: 20806349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
    Lin TS; Donohue KA; Byrd JC; Lucas MS; Hoke EE; Bengtson EM; Rai KR; Atkins JN; Link BK; Larson RA
    J Clin Oncol; 2010 Oct; 28(29):4500-6. PubMed ID: 20697069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
    Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
    Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
    Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
    Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
    Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
    Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
    Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
    Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
    Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Parikh SA; Keating MJ; O'Brien S; Wang X; Ferrajoli A; Faderl S; Burger J; Koller C; Estrov Z; Badoux X; Lerner S; Wierda WG
    Blood; 2011 Aug; 118(8):2062-8. PubMed ID: 21750315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia.
    Kaufman MS; Caramanica A; Janson D; Driscoll N; Johnson C; Kohn N; Wasil T; Rai KR
    Med Oncol; 2011 Jun; 28(2):532-8. PubMed ID: 20237867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
    Zent CS; Call TG; Shanafelt TD; Tschumper RC; Jelinek DF; Bowen DA; Secreto CR; Laplant BR; Kabat BF; Kay NE
    Cancer; 2008 Oct; 113(8):2110-8. PubMed ID: 18759253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
    Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
    Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).
    Galimberti S; Cervetti G; Cecconi N; Fazzi R; Pacini S; Guerrini F; Manetti C; Caracciolo F; Petrini M
    J Immunother; 2004; 27(5):389-93. PubMed ID: 15314547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Keating MJ; Flinn I; Jain V; Binet JL; Hillmen P; Byrd J; Albitar M; Brettman L; Santabarbara P; Wacker B; Rai KR
    Blood; 2002 May; 99(10):3554-61. PubMed ID: 11986207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.
    Rawstron AC; Kennedy B; Moreton P; Dickinson AJ; Cullen MJ; Richards SJ; Jack AS; Hillmen P
    Blood; 2004 Mar; 103(6):2027-31. PubMed ID: 14630811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
    Hillmen P; Skotnicki AB; Robak T; Jaksic B; Dmoszynska A; Wu J; Sirard C; Mayer J
    J Clin Oncol; 2007 Dec; 25(35):5616-23. PubMed ID: 17984186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
    Hale G; Rebello P; Brettman LR; Fegan C; Kennedy B; Kimby E; Leach M; Lundin J; Mellstedt H; Moreton P; Rawstron AC; Waldmann H; Osterborg A; Hillmen P
    Blood; 2004 Aug; 104(4):948-55. PubMed ID: 15090452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.